Related Experiment Video
Updated: Nov 1, 2025
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Dinuclear orthometallated gold(I)-gold(III) anticancer complexes with potent in vivo activity through an
Nedaossadat Mirzadeh1, Srinivasa Reddy Telukutla1, Rodney Luwor2
1Centre for Advanced Materials and Industrial Chemistry (CAMIC), School of Science, RMIT University, GPO Box 2476, Melbourne, Victoria, 3001, Australia.
Abstract:
Increasingly explored over the last decade, gold complexes have shown great promise in the field of cancer therapeutics. A major obstacle to their clinical progression has been their lack of in vivo stability, particularly for gold(III) complexes, which often undergo a facile reduction in the presence of biomolecules such as glutathione. Herein, we report a new class of promising anticancer gold(I)-gold(III) complexes with the general formula [XAuI(μ-2-C6F4PPh2)(κ2-2-C6F4PPh2)AuIIIX] [X = Cl (1), Br (2), NO3 (3)] which feature two gold atoms in different oxidation states (I and III) in a single molecule. Interestingly, gold(I)-gold(III) complexes (1-3) are stable against glutathione reduction under physiological-like conditions. In addition, complexes 1-3 exhibit significant cytotoxicity (276-fold greater than cisplatin) toward the tested cancer cells compared to the noncancerous cells. Moreover, the gold(I)-gold(III) complexes do not interact with DNA-like cisplatin but target cellular thioredoxin reductase, an enzyme linked to the development of cisplatin drug resistance. Complexes 1-3 also showed potential to inhibit cancer and endothelial cell migration, as well as tube formation during angiogenesis. In vivo studies in a murine HeLa xenograft model further showed the gold compounds may inhibit tumor growth on par clinically used cisplatin, supporting the significant potential this new compound class has for further development as cancer therapeutic.
Insights
New gold(I)-gold(III) complexes show enhanced stability and potent anticancer activity, outperforming cisplatin by targeting thioredoxin reductase and inhibiting tumor growth in vivo.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Cancer Therapeutics
Background:
- Gold complexes are promising anticancer agents, but clinical progression is hindered by poor in vivo stability, especially for gold(III) species.
- Gold(III) complexes are susceptible to reduction by biomolecules like glutathione under physiological conditions.
- Developing stable and effective gold-based cancer drugs remains a significant challenge.
Purpose of the Study:
- To synthesize and characterize a novel class of gold(I)-gold(III) complexes.
- To evaluate the in vitro and in vivo anticancer efficacy and stability of these bimetallic gold complexes.
- To investigate the mechanism of action, focusing on interactions with biomolecules and enzymes relevant to cancer drug resistance.
Main Methods:
- Synthesis of gold(I)-gold(III) complexes with the general formula [XAuI(μ-2-C6F4PPh2)(κ2-2-C6F4PPh2)AuIIIX].
- Assessment of stability against glutathione reduction under physiological conditions.
- Evaluation of cytotoxicity against cancer and noncancerous cell lines.
- Investigation of DNA interaction and thioredoxin reductase inhibition.
- Assessment of anti-migratory and anti-angiogenic effects.
- In vivo efficacy studies using a murine HeLa xenograft model.
Main Results:
- The synthesized gold(I)-gold(III) complexes (1-3) demonstrated remarkable stability against glutathione reduction.
- Complexes 1-3 exhibited significant cytotoxicity, up to 276-fold greater than cisplatin, against tested cancer cells.
- Unlike cisplatin, these complexes did not interact with DNA but effectively targeted thioredoxin reductase.
- The gold compounds showed potential to inhibit cancer and endothelial cell migration and angiogenesis.
- In vivo studies indicated that the gold compounds inhibited tumor growth comparably to cisplatin.
Conclusions:
- The novel gold(I)-gold(III) complexes offer improved stability and superior anticancer activity compared to cisplatin.
- These complexes represent a promising new class of cancer therapeutics with a unique mechanism of action targeting thioredoxin reductase.
- Further development of these bimetallic gold compounds holds significant potential for clinical application in cancer treatment.
More Related Videos
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
09:00An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
Published on: March 18, 2015
